Approaches for assessing risks to sensitive populations: Lessons learned from evaluating risks in the pediatric population

Toxicological Sciences

Volumn 113, Issue 1, 2009, Pages 4-26

  Hines, Ronald N ^a   Sargent, Dana ^b   Autrup, Herman ^c   Birnbaum, Linda S ^d   Brent, Robert L ^e   Doerrer, Nancy G ^f   Cohen Hubal, Elaine A ^g   Juberg, Daland R ^h   Laurent, Christian ⁱ   Luebke, Robert ^g   Olejniczak, Klaus ^h   Portier, Christopher J ^j   Slikker, William ^k  

^a Children's Hospital of Wisconsin   (United States)

^b BAYER CROPSCIENCE   (United States)

^c AARHUS UNIVERSITY   (Denmark)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^f International Life Sciences Institute   (United States)

^g U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^h DOW AGROSCIENCES LLC   (United States)

ⁱ EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^j Federal Institute for Drugs and Medical Devices   (Germany)

^k NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

more..

Author keywords

Exposure assessment; Genetic variability; Pediatric population; Pharmacodynamics; Pharmacokinetics; Risk assessment; Sensitive populations

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; DIMETHYLANILINE MONOOXYGENASE; DNA; ESTROGEN SULFOTRANSFERASE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

BIOLOGICAL MONITORING; CARCINOGENICITY; CHILD; CHILD HEALTH CARE; CHILD SAFETY; DISEASE PREDISPOSITION; DNA REPAIR; ENVIRONMENTAL EXPOSURE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH CARE ORGANIZATION; HEREDITY; HUMAN; IMMUNOTOXICITY; MEDICAL LITERATURE; METHODOLOGY; NEUROTOXICITY; PERINATAL DRUG EXPOSURE; POPULATION RESEARCH; PRENATAL EXPOSURE; REVIEW; RISK ASSESSMENT; TOXICITY TESTING; TOXICOKINETICS; TOXICOLOGY;

ADOLESCENT; ADULT; AGE FACTORS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL MONITORING; GENETIC PREDISPOSITION TO DISEASE; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; INFANT; INFANT, NEWBORN; MODELS, BIOLOGICAL; PHARMACOKINETICS; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTORS; TOXICITY TESTS;

EID: 75249097838     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp217     Document Type: Review

References (143)

1. Albertini, R., Bird, M., Doerrer, N., Needham, L., Robison, S., Sheldon, L., and Zenick, H. (2006). The use of biomonitoring data in exposure and human health risk assessment. Environ. Health Perspect. 114, 1755-1762.
2. Alcorn, J., and McNamara, P.J. (2002). Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin. Pharmacokinet. 41, 959-998.
3. American Cancer Society. (2008). Cancer Facts and Figures. American Cancer Society, Atlanta, GA.
4. Ames, B.N., and Gold, L.S. (1990). Chemical carcinogenesis: too many rodent carcinogens. Proc. Natl. Acad. Sci. U.S.A. 87, 7772-7776.
5. Anderson, L.M., Diwan, B.A., Fear, N.T., and Roman, E. (2000). Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ. Health Perspect. 108(Suppl. 3), 573-594.
6. Barr, D.B., Wang, R.Y., and Needham, L.L. (2005). Biologic monitoring of exposure to environmental chemicals throughout the life stages: requirements and issues for consideration for the National Children's Study. Environ. Health Perspect. 113, 1083-1091.
7. Barter, Z.E., Bayliss, M.K., Beaune, P.H., Boobis, A.R., Carlile, D.J., Edwards, R.J., Houston, J.B., Lake, B.G., Lipscomb, J.C., Pelkonen, O.R., et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8, 33-45.
8. Barter, Z.E., Chowdry, J.E., Harlow, J.R., Snawder, J.E., Lipscomb, J.C., and Rostami-Hodjegan, A. (2008). Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos. 36, 2405-2409.
9. Bearer, C.F. (1995). How are children different from adults? Environ. Health Perspect. 103, 7-12.
10. Beck, B.D., Mattuck, R.L., Bowers, T.S., Cohen, J.T., and O'Flaherty, E. (2001). The development of a stochastic physiologically-based pharmaco-kinetic model for lead. Sci. Total Environ. 274, 15-19.
11. Bellinger, D.C. (2007). Children's cognitive health: the influence of environmental chemical exposures. Altern. Ther. Health Med. 13, S140-S144.
12. Bleyer, A., Viny, A., and Barr, R. (2006). Cancer in 15-to 29-year-olds by primary site. Oncologist 11, 590-601.
13. Boersma, E.R., and Lanting, C.I. (2000). Environmental exposure to polychlorinated biphenyls (PCBs) and dioxins. Consequences for long-term neurological and cognitive development of the child lactation. Adv. Exp. Med. Biol. 478, 271-287.
14. Boice, J.D., Jr, and Miller, R.W. (1999). Childhood and adult cancer following intrauterine exposure to ionizing radiation. Teratology 59, 227-233.
15. Boice, J.D., Jr, Tawn, E.J., Winther, J.F., Donaldson, S.S., Green, D.M., Mertens, A.C., Mulvihill, J.J., Olsen, J.H., Robison, L.L., and Stovall, M. (2003). Genetic effects of radiotherapy for childhood cancer. Health Phys. 85, 65-80.
16. Brenner, S.S., and Klotz, U. (2004). p-Glycoprotein function in the elderly. Eur. J. Clin. Pharmacol. 60, 97-102.
17. Brent, R.L. (1994). Biological factors related to male mediated reproductive and developmental toxicity. In Male-Mediated Developmental Toxicity (A. F. Olsah and D.R. Mattison, Eds.), pp. 209-242. Plenum Press, New York.
18. Brent, R.L. (1999). Utilization of developmental basic science principles in the evaluation of reproductive risks from pre-and post-conception environmental radiation exposures. Paper presented at: Thirty-third Annual Meeting of the National Council on Radiation Protection and Measurements: the Effects of Pre-and Post-conception Exposure to Radiation, April 2-3, 1997, Arlington, VA. Teratology 59, 182-204.
19. Brent, R. (2007). Lauriston S. Taylor lecture: fifty years of scientific research: the importance of scholarship and the influence of politics and controversy. Health Phys. 93, 348-379.
20. Brent, R.L., Tanski, S., and Weitzman, M. (2004). A pediatric perspective on the unique vulnerability and resilience of the embryo and child to environmental toxicants: the importance of rigorous research concerning age and agent. Pediatrics 113, 935-944.
21. Brent, R.L., and Weitzman, M. (2004). The vulnerability, sensitivity, and resiliency of the developing embryo, infant, child, and adolescent to the effects of environmental chemicals, drugs, and physical agents as compared to the adult. Pediatrics 113, 933-1172.
22. Brown, R.C., Barone, S., Jr, and Kimmel, C.A. (2008). Children's health risk assessment: incorporating a lifestage approach into the risk assessment process. Birth Defects Res. (Part B) 83, 511-521.
23. Byrne, J. (1999). Long-term genetic and reproductive effects of ionizing radiation and chemotherapeutic agents on cancer patients and their offspring. Teratology 59, 210-215.
24. Caldwell, M.D., Awad, T., Johnson, J.A., Gage, B.F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T.Y., Eby, C., et al. (2008). CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112.
25. Chang, T.W., and Pan, A.Y. (2008). Cumulative environmental changes, skewed antigen exposure, and the increase of allergy. Adv. Immunol. 98, 39-83.
26. Clewell, H.J., Gentry, P.R., Covington, T.R., Sarangapani, R., and Teeguarden, J.G. (2004). Evaluation of the potential impact of age-and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79, 381-393.
27. Clewell, R.A., Merrill, E.A., Gearhart, J.M., Robinson, P.J., Sterner, T.R., Mattie, D.R., and Clewell, H.J., 3rd. (2007). Perchlorate and radioiodide kinetics across life stages in the human: using PBPK models to predict dosimetry and thyroid inhibition and sensitive subpopulations based on developmental stage. J. Toxicol. Environ. Health A 70, 408-428.
28. Cohen, S.M., Anderson, T.A., de Oliveria, L.M., and Arnold, L.L. (1998). Tumorigenicity of sodium ascorbate in male rats. Cancer Res. 58, 2557-2561.
29. Cohen, S.M., Garland, E.M., Cano, M., St. John, M.K., Khachab, M., Wehner, J.M., and Arnold, L.L. (1995). Effects of sodium ascorbate, sodium saccharin and ammonium chloride in the male rat urinary bladder. Carcinogenesis 16, 2743-2750.
30. Cohen Hubal, E.A., Moya, J., and Selevan, S.G. (2008). A lifestage approach to assessing children's exposure. Birth Defects Res. (Part B) 83, 522-529.
31. Cohen Hubal, E.A., Sheldon, L.S., Burke, J.M., McCurdy, T.R., Berry, M.R., and Rigas, M.L. (2000a). Children's exposure assessment: a review of factors influencing children's exposure, and the data available to characterize and assess that exposure. Environ. Health Perspect. 108, 475-486.
32. Cohen Hubal, E.A., Sheldon, L.S., Zufall, M.J., Burke, J.M., and Thomas, K. (2000b). The challenge of assessing children's residential exposure to pesticides. J. Exp. Anal. Environ. Epidemiol. 10, 638-649.
33. Cole, T.B., Jampsa, R.L., Walter, B.J., Arndt, T.L., Richter, R.J., Shih, D.M., Tward, A., Lusis, A.J., Jack, R.M., Costa, L.G., et al. (2003). Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13, 357-364.
34. Cole, T.B., Walter, B.J., Shih, D.M., Tward, A.D., Lusis, A.J., Timchalk, C., Richter, R.J., Costa, L.G., and Furlong, C.E. (2005). Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet. Genom. 15, 589-598.
35. Conn, P.J., and Pin, J.P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol 37, 205-237.
36. Cory-Slechta, D.A. (2005). Studying toxicants as single chemicals: does this strategy adequately identify neurotoxic risk? Neurotoxicol. 26, 491-510.
37. Cresteil, T., Beaune, P., Kremers, P., Flinois, J.P., and Leroux, J.P. (1982). Drug-metabolizing enzymes in human foetal liver: partial resolution of multiple cytochromes P450. Pediatric Pharmacol. 2, 199-207.
38. D'Amato, G., Liccardi, G., D'Amato, M., and Holgate, S. (2005). Environmental risk factors and allergic bronchial asthma. Clin. Exp. Allergy 35, 1113-1124.
39. Daston, G., Faustman, E., Ginsberg, G., Fenner-Crisp, P., Olin, S., Sonawane, B., Bruckner, J., Breslin, W., and McLaughlin, T.J. (2004). A framework for assessing risks to children from exposure to environmental agents. Environ. Health Perspect. 112, 238-256.
40. deFur, P.L., Evans, G.W., Cohen Hubal, E.A., Kyle, A.D., Morello-Frosch, R.A., and Williams, D. (2007). Vulnerability as a function of individual and group resources in cumulative risk assessment. Environ. Health Perspect. 115, 817-824.
41. Dietert, R.R., and Piepenbrink, M.S. (2006a). Perinatal immunotoxicity: why adult exposure assessment fails to predict risk. Environ. Health Perspect. 114, 477-483.
42. Dietert, R.R., and Piepenbrink, M.S. (2006b). Lead and immune function. Crit. Rev. Toxicol. 36, 359-385.
43. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S.F. (1999). The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61.
44. Djemli, A., Van Vliet, G., and Delvin, E.E. (2006). Congenital hypothyroidism: from paracelsus to molecular diagnosis. Clin. Biochem. 39, 511-518.
45. Done, A.K. (1964). Developmental pharmacology. Clin. Pharmacol. Ther. 5, 432-479.
46. Eaton, D.L. (2000). Biotransformation enzyme polymorphism and pesticide susceptibility. Neurotoxicology 21, 101-112.
47. Edginton, A.N., Schmitt, W., Voith, B., and Willmann, S. (2006). A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45, 683-704.
48. Estrada, L., Kanelakis, K.C., Levy, G.N., and Weber, W.W. (2000). Tissue-and gender-specific expression of N-acetyltransferase 2 (Nat2*) during development of the outbred mouse strain CD-1. Drug. Metab. Dispos. 28, 139-146.
49. Euling, S.Y., and Kimmel, C.A. (2001). Developmental stage sensitivity and mode of action information for androgen agonists and antagonists. Sci. Total Environ. 274, 103-113.
50. Faustman, E.M., Silbernagel, S.M., Fenske, R.A., Burbacher, T.M., and Ponce, R.A. (2000). Mechanisms underlying children's susceptibility to environmental toxicants. Environ. Health Perspect. 108(Suppl. 1), 13-21.
51. Firestone, M., Moya, J., Cohen Hubal, E., and Zartarian, V. (2007). Identifying childhood age groups for exposure assessments and monitoring. Risk Anal. 27, 701-714.
52. Ginsberg, G., Hattis, D., Russ, A., and Sonawane, B. (2004a). Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health A 67, 297-329.
53. Ginsberg, G., Slikker, W., Jr, Bruckner, J., and Sonawane, B. (2004b). Incorporating children's toxicokinetics into a risk framework. Environ. Health Perspect. 112, 272-283.
54. Goldman, L.R. (1995). Children-unique and vulnerable environmental risks facing children and recommendations for response. Environ. Health Perspect. 103(Suppl. 6), 13-18.
55. Guilarte, T.R. (1997). PB2+ inhibits NMDA receptor function at high and low affinity sites: developmental and regional brain expression. Neurotoxicology 18, 43-51.
56. Hakkola, J., Pasanen, M., Purkunen, R., Saarikoski, S., Pelkonen, O., Mäenpää, J., Rane, A., and Raunio, H. (1994). Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem. Pharmacol. 48, 59-64.
57. Hall, E. (2002). Lessons we have learned from our children: cancer risks from diagnostic radiology. Pediatr. Radiol. 32, 700-706.
58. Herbst, A.L., Ulfelder, H., and Poskanzer, D.C. (1971). Adenocarcinoma of the vagina: an association of maternal stilbestrol therapy with tumor appearing in young women. N. Engl. J. Med. 284, 878-881.
59. Hines, R.N. (2008). Ontogeny of drug metabolism enzymes and implications for adverse drug reactions. Pharmacol. Ther. 118, 250-267.
60. Holladay, S.D., and Smialowicz, R.J. (2000). Development of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure. Environ. Health Perspect. 108(Suppl. 3), 463-473.
61. Hong, J.Y., and Yang, C.S. (1997). Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environ. Health Perspect. 105(Suppl. 4), 759-762.
62. Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vockler, J., and Dikranian, K. (1999). Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283, 70-74.
63. Johnson, T.N., Rostami-Hodjegan, A., and Tucker, G.T. (2006). Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45, 931-956.
64. Johnsrud, E.K., Koukouritaki, S.B., Divakaran, K., Brunengraber, L., Hines, R.N., and McCarver, D.G. (2003). Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 307, 402-407.
65. Kearns, G.L., Robinson, P.K., Wilson, J.T., Wilson-Costello, D., Knight, G.R., and Ward, R.M. (2003). Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin. Pharmacol. Ther. 74, 312-325.
66. Kimmel, G.L. (2005). An overview of children as a special population-relevance to predictive biomarkers. Toxicol. Appl. Pharmacol. 206, 215-218.
67. Kitada, M., Taneda, M., Itahashi, K., and Kamataki, T. (1991). Four forms of cytochrome P-450 in human fetal liver: purification and their capacity to activate promutagens. Jpn. J. Cancer Res. 82, 426-432.
68. Koukouritaki, S.B., Manro, J.R., Marsh, S.A., Stevens, J.C., Rettie, A.E., McCarver, D.G., Hines, R., and N (2004). Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308, 965-974.
69. Kumari, M., and Ticku, M.K. (1998). Ethanol and regulation of the NMDA receptor subunits in fetal cortical neurons. J. Neurochem. 70, 1467-1473.
70. Kwabi-Addo, B., Chung, W., Shen, L., Ittmann, M., Wheeler, T., Jelinek, J., and Issa, J.P. (2007). Age-related DNA methylation changes in normal human prostate tissues. Clin. Cancer Res. 13, 3796-3802.
71. Kyle, A.D., Woodruff, T.J., and Axelrad, D.A. (2006). Integrated assessment of environment and health: America's children and the environment. Environ. Health Perspect. 114, 447-452.
72. Lea, P.M., IV, and Faden, A I. (2006). Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 12, 149-166.
73. Lee, Q.P., Fantel, A.G., and Juchau, M.R. (1991). Human embryonic cytochrome P450S: phenoxazone ethers as probes for expression of functional isoforms during organogenesis. Biochem. Pharmacol. 42, 2377-2385.
74. Lewin, B. (1997). In Gene VI. Oxford University Press, Oxford.
75. Liao, K.H., Tan, Y.M., Conolly, R.B., Borghoff, S., J, Gargas, M.L., Andersen, M.E., and Clewell, H.J., 3rd. (2007). Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal. 27, 1535-1551.
76. Lin, H.J., Han, C.Y., Lin, B.K., and Hardy, S. (1993). Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am. J. Hum. Genet. 52, 827-834.
77. Luebke, R.W., Chen, D.H., Dietert, R., Yang, Y., King, M., and Luster, M.I. (2006). The comparative immunotoxicity of five selected compounds following developmental or adult exposure. J. Toxicol. Environ. Health B Crit. Rev. 9, 1-26.
78. Luebke, R.W., Parks, C., and Luster, M.I. (2004). Suppression of immune function and susceptibility to infections in humans: association of immune function with clinical disease. J. Immunotoxicol. 1, 15-24.
79. Makri, A., Goveia, M., Balbus, J., and Parkin, R. (2004). Children's susceptibility to chemicals: a review by developmental stage. J. Toxicol. Environ. Health B Crit. Rev. 7, 417-435.
80. Makris, S.L., Thompson, C.M., Euling, S.Y., Selevan, S.G., and Sonawane, B. (2008). A lifestage-specific approach to hazard and dose-response characterization for children's health risk assessment. Birth Defects Res. (Part B) 83, 530-546.
81. Mayatepek, E., and Kohlmüeller, D. (1998). Transient trimethylaminuria in childhood. Acta Paediatr. 87, 1205-1207.
82. McCarver, D.G. (2004). Applicability of the principles of developmental pharmacology to the study of environmental toxicants. Pediatrics 113(Suppl. 4), 969-972.
83. Miyamoto, K., Nakanishi, H., Moriguchi, S., Fukuyama, N., Eto, K., Wakamiya, J., Murao, K., Arimura, K., and Osame, M. (2001). Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity. Brain Res. 901, 252-258.
84. Mulvihill, J., Connelly, R.R., Austin, D.F., Bragg, K., Cook, J.W., Hassinger, D.D., Holmes, F.F., and Holmes, D.F. (1987). Cancer in offspring of long-term survivors of childhood and adolescent cancer. Lancet 2, 813-817.
85. Murry, D.J., Crom, W.R., Reddick, W.E., Bhargava, R., and Evans, W.E. (1995). Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab. Dispos. 23, 1110-1116.
86. Nakano, M., Kodama, Y., Ohtaki, K., Nakashima, E., Niwa, O., Toyoshima, M., and Nakamura, N. (2007). Chromosome aberrations do not persist in the lymphocytes or bone marrow cells of mice irradiated in utero or soon after birth. Radiat. Res. 167, 693-702.
87. Napier, K. (2003). Real risks vs hyped fears. In Are Children More Vulnerable to Environmental Chemicals? (D. R. Juberg, Ed.), pp. 193-215. American Council on Science and Health, New York.
88. National Academies of Sciences. (1993). Pesticides in the Diets of Infants and Children. National Academies Press, Washington, DC.
89. National Environmental Justice Advisory Council. (2004). Ensuring risk reduction in communities with multiple stressors: environmental justice and cumulative risks/impacts. US Environmental Protection Agency NEJAC Cumulative Risks/Impacts Work Group, Washington, DC. Available at: http://www.epa.gov/compliance/resources/publications/ej/nejac/nejac-cum-risk-rpt-122104.pdf. Accessed 2008.
90. National Research Council. (1987). Biological markers in environmental health research. Committee on Biological Markers of the National Research Council. Environ. Health Perspect. 74, 3-9.
91. Needham, L.L., Özkaynak, H., Whyatt, R.M., Barr, D.B., Wang, R.Y., Naeher, L., Akland, G., Bahadori, T., Bradman, A., Fortmann, R., et al. (2005). Exposure assessment in the National Children's Study: introduction. Environ. Health Perspect. 113, 1076-1082.
92. Neel, J.V. (1999). Changing perspectives on the genetic doubling dose of ionizing radiation for humans, mice, and Drosophila. Teratology 59, 216-222.
93. Neel, J.V., and Lewis, S.E. (1990). The comparative radiation genetics of humans and mice. Am. Rev. Genet. 24, 327-362.
94. Neri, M., Ugolini, D., Bonassi, S., Fucic, A., Holland, N., Knudsen, L.E., Srám, R. J., Ceppi, M., Bocchini, V., and Merlo, D.F. (2006). Children's exposure to environmental pollutants and biomarkers of genetic damage. II. Results of a comprehensive literature search and meta-analysis. Mutat. Res. 612, 14-39.
95. Noda, T., Todani, T., Watanabe, Y., and Yamamoto, S. (1997). Liver volume in children measured by computed tomography. Pediatr. Radiol. 27, 250-252.
96. Nong, A., McCarver, D.G., Hines, R.N., and Krishnan, K. (2006). Physiologically-based modeling of inter-child differences in pharmacokinetics on the basis of subject-specific data on hepatic CYP2E1 levels. Toxicol. Appl. Pharmacol. 214, 78-87.
97. Nygaard, R., Clausen, N., Simes, M.A., Márky, I., Skjeldestad, F.E., Kristinsson, J.R., Vuoristo, A., Wegelius, R., and Moe, P.J. (1991a). Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring. Med. Pediatr. Oncol. 19, 459-466.
98. Nygaard, R., Garwicz, S., Haldorsen, T., Hertz, H., Jonmundsson, G.K., Lanning, M., and Moe, P.J. (1991b). Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (NOPHO). Acta Paediatr. Scand. 80, 1220-1228.
99. Özkaynak, H., Whyatt, R.M., Needham, L.L., Akland, G., and Quackenboss, J. (2005). Exposure assessment implications for the design and implementation of the National Children's Study. Environ. Health Perspect. 113, 1108-1115.
100. Pasanen, M., Pelkonen, O., Kauppila, A., Park, S.S., Friedman, F.K., and Gelboin, H.V. (1987). Characterization of human fetal hepatic cytochrome P-450-associated 7-ethoxyresofufin O-deethylase and aryl hydrocarbon hydroxylase activities by monoclonal antibodies. Dev. Pharmacol. Ther. 10, 125-132.
101. Pearce, R.E., Gotschall, R.R., Kearns, G.L., and Leeder, J.S. (2001). Cytochrome P450 involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual CYP3A isoforms. Drug Metab. Dispos. 29, 1548-1554.
102. Piccinni, M.P., Scaletti, C., Maggi, E., and Ramagnani, S. (2000). Role of hormone-controlled Th1-and Th2-type cytokines in successful pregnancy. J. Neuroimmunol. 109, 30-33.
103. Pohl, H.R., van Engelen, J.G., Wilson, J., and Sips, A.J. (2005). Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report. Reg. Toxicol. Pharmacol. 42, 83-95.
104. Popke, E.J., Allen, R.R., Pearson, E.C., Hammond, T.G., and Paule, M.G. (2001a). Differential effects of two NMDA receptor antagonists on cognitive-behavioral development in nonhuman primates I. Neurotoxicol. Teratol. 23, 319-332.
105. Popke, E.J., Allen, R.R., Pearson, E.C., Hammond, T.G., and Paule, M.G. (2001b). Differential effects of two NMDA receptor antagonists on cognitive-behavioral performance in young nonhuman primates II. Neurotoxicol. Teratol. 23, 333-347.
106. Portier, C.J., and Bell, D.A. (1998). Genetic susceptibility: significance in risk assessment. Toxicol. Lett. 102-103, 185-189.
107. Preston, D.L., Cullings, H., Suyama, A., Funamoto, S., Nishi, N., Soda, M., Mabuchi, K., Kodama, K., Kasagi, F., and Shore, R.E. (2008). Solid cancer incidence in atomic bomb survivors exposed in utero or as young children. J. Natl. Cancer Inst. 100, 428-436.
108. Reichrath, J. (2006). DNA repair mechanisms: underestimated key players for cancer prevention and therapy. J. Mol. Histol. 37, 179-181.
109. Reiss, R., Anderson, E.L., and Lape, J. (2003). A framework and case study for exposure assessment in the Voluntary Children's Chemical Evaluation Program. Risk Anal. 23, 1069-1084.
110. Scheetz, A.J., and Constantine-Paton, M. (1994). Modulation of NMDA receptor function: implications for vertebrate neural development. FASEB J. 8, 745-752.
111. Scheuplein, R., Charnley, G., and Dourson, M. (2002). Differential sensitivity of children and adults to chemical toxicity. Biological basis. Reg. Toxicol. Pharmacol. 35, 429-447.
112. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K., and Kamali, F. (2005). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333.
113. Seed, J., Carney, E.W., Corley, R.A., Crofton, K.M., DeSesso, J.M., Foster, P.M., Kavlock, R., Kimmel, G., Klaunig, J., Meek, M.E., et al. (2005). Overview: using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit. Rev. Toxicol. 35, 663-672.
114. Selevan, S.G., Kimmel, C.A., and Mendola, P. (2000). Identifying critical windows of exposure for children's health. Environ. Health Perspect. 108(Suppl. 3), 451-455.
115. Slikker, W., Jr, Andersen, M.E., Bogdanffy, M.S., Bus, J.S., Cohen, S.D., Conolly, R.B., David, R.M., Doerrer, N.G., Dorman, D.C., Gaylor, D.W., et al. (2004). Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol. 201, 203-225.
116. Slikker, W., Jr, and Chang, L.W. (1998). In Handbook of Developmental Neurotoxicology. Academic Press, San Diego, CA.
117. Stephenson, T. (2005). How children's responses to drugs differ from adults. Br. J. Clin. Pharmacol. 59, 670-673.
118. Stewart, A.M. (1973). The carcinogenic effects of low-level radiation: a reappraisal of epidemiologists' methods and observations. Health Phys. 24, 223-240.
119. Stewart, A.M., and Kneale, G.W. (1970). Radiation dose effects in relation to obstetric x-rays and childhood cancers. Lancet 1, 1185-1188.
120. Stewart, A.M., Webb, D., and Hewitt, D. (1958). A survey of childhood malignancies. Br. Med. J. 1, 1495-1508.
121. Tham, L.S., Goh, B.C., Nafziger, A., Guo, J.Y., Wang, L.Z., Soong, R., and Lee, S.C. (2006). A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355.
122. Timchalk, C., Nolan, R.J., Mendrala, A.L., Dittenber, D.A., Brzak, K.A., and Mattsson, J.L. (2002). A physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 66, 34-53.
123. Treluyer, J.-M., Rey, E., Sonnier, M., Pons, G., and Cresteil, T. (2001). Evidence of impaired cisapride metabolism in neonates. Br. J. Clin. Pharmacol. 52, 419-425.
124. U.S. Environmental Protection Agency (USEPA). (2003a). Guidelines for carcinogen risk assessment. EPA/630/R-03/003. US Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Washington, DC. Available at: http://www.epa.gov/ncea/raf/cancer2003.htm. Accessed 2008.
125. U.S. Environmental Protection Agency (USEPA). (2003b). Framework for cumulative risk assessment. EPA/630/P-02/001F. U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC. Available at: http://cfpub.epa.gov/ncea/raf/recordisplay.cfm?deid=54944. Accessed 2008.
126. U.S. Environmental Protection Agency (USEPA). (2005a). Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. EPA/630/R-03/003F. U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC. Available at: http://www.epa.gov/ttn/atw/childrens_supplement_final.pdf. Accessed 2008.
127. U.S. Environmental Protection Agency (USEPA). (2005b). Guidance on selecting age groups for monitoring and assessing childhood exposures to environmental contaminants. EPA/630/P-03/003F. U.S. Environmental Protection Agency, Risk Assessment Forum, Washington, DC. Available at: http://cfpub2.epa.gov/ncea/cfm/recordisplay.cfm?deid=146583. Accessed 2008.
128. U.S. Environmental Protection Agency (USEPA). (2006a). A framework for assessing health risks of environmental exposures to children. EPA/600/R-05/093F. U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Washington, DC. Available at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=158363. Accessed 2008.
129. U.S. Environmental Protection Agency (USEPA). (2006b). Child-specific exposure factors handbook (external review draft). EPA/600/R-06/096A. U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Washington, DC. Available at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=56747. Accessed 2008.
130. U.S. Environmental Protection Agency (USEPA). (2008). Physiological parameters database for older adults 1.0 (beta). U.S. Environmental Protection Agency, Office of Research and Development, National Center for Environmental Assessment, Washington, DC. Available at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=188288. Accessed 2008.
131. U.S. Food and Drug Administration (USFDA). (2000). E11 clinical investigation of medicinal products in the pediatric population. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Washington, DC. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm129476.htm. Accessed 2008.
132. Vingerhoets, A.J., Assies, J., Goodkin, K., Van Heck, G.L., and Bekker, M.H. (1998). Prenatal diethylstilbestrol exposure and self-reported immune-related diseases. Eur. J. Obstet. Gynecol. Reprod. Biol. 77, 205-209.
133. Wang, F., Chang, D., Hu, F.L., Sui, H., Han, B., Li, D.D., and Zhao, Y.S. (2008). DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies. Cancer Epidemiol. Biomarkers Prev. 17, 507-517.
134. Wedlund, P.J. (2000). The CYP2C19 enzyme polymorphism. Pharmacology 61, 174-183.
135. Wei, Q., Li, L., and Chen, D.J., Eds. 2007. DNA Repair, Genetic Instability and Cancer. World Scientific Publishing Co., Hackensack, NJ.
136. Weisglas-Kuperus, N., Patandin, S., Berbers, G.A., Sas, T.C., Mulder, P.G., Sauer, P.J., and Hooijkaas, H. (2000). Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children. Environ. Health Perspect. 108, 1203-1207.
137. Weiss, C.F., Glazko, A.J., and Weston, J.K. (1960). Chloramphenicol in the newborn infant: a physiological explanation of its toxicity when given in excessive doses. N. Engl. J. Med. 262, 787-794.
138. Willhite, C.C., Ball, G.L., and McLellan, C.J. (2008). Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration. J. Toxicol. Environ. Health B Crit. Rev. 11, 69-146.
139. Wilson, J.M.G., and Jungner, G. (1968). Principles and practice of screening for disease. In Screening for Inborn Errors of Metabolism, Technical Series No. 401, p. 163. World Health Organization, Geneva, Switzerland.
140. Winther, J.F., Boice, J.D., Jr, Mulvihill, J., Stovall, M., Frederiksen, K., Tawn, E.J., and Olsen, J.H. (2004). Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a population-based study. Am. J. Human Genet. 74, 1282-1285.
141. Wood, R. (1997). Nucleotide excision repair in mammalian cells. J. Biol. Chem. 272, 23465-23468.
142. World Health Organization (WHO). (2006). Principles for evaluating health risks in children associated with exposure to chemicals (draft). International Programme on Chemical Safety Environmental Health Criteria document (EHC-237). World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland Available at: http://www.who.int/ipcs/features/ehc/en/index.html. Accessed 2008.
143. Zaya, M.J., Hines, R.N., and Stevens, J.C. (2006). Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab. Dispos. 34, 2097-2101.